Wealth Enhancement Advisory Services’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-50,000
Closed -$7K 2891
2024
Q2
$7K Buy
+50,000
New +$101K ﹤0.01% 2531

Other funds holding PACB

Wealth Enhancement Advisory Services's PACB Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Pacific Biosciences (PACB) stake by 26% in Q2 2026, buying an estimated $16.5K and bringing the position to 54,981 shares worth $85.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3833.

Wealth Enhancement Advisory Services first reported a position in PACB in Q3 2023 and has held it in 12 quarters since. The position peaked at $162K in Q4 2023. 27 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Wealth Enhancement Advisory Services held 54,981 shares of Pacific Biosciences worth $85.8K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 11,320 Pacific Biosciences shares in Q2 2026, an estimated $16.5K.
  • Pacific Biosciences made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3833 holding.
  • Wealth Enhancement Advisory Services first reported a position in Pacific Biosciences in Q3 2023 and has held it in 12 quarters since.
  • Wealth Enhancement Advisory Services's Pacific Biosciences position peaked at $162K in Q4 2023.
  • 27 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.